anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Obesity is a risk factor for developing severe COVID-19. However, the mechanism underlying obesity-accelerated COVID-19 remains unclear. Here, we report results from a study in which 2-3-month-old K18-hACE2 (K18) mice were fed a western high-fat diet (WD) or normal chow (NC) over 3 months before intranasal infection with a sublethal dose of SARS-CoV2 WA1 (a strain ancestral to the Wuhan variant). After infection, the WD-fed K18 mice lost significantly more body weight and had more severe lung inflammation than normal chow (NC)-fed mice. Bulk RNA-seq analysis of lungs and adipose tissue revealed a diverse landscape of various immune cells, inflammatory markers, and pathways upregulated in the infected WD-fed K18 mice when compared with the infected NC-fed control mice. The transcript levels of IL-6, an important marker of COVID-19 disease severity, were upregulated in the lung at 6-9 days post-infection in the WD-fed mice when compared to NC-fed mice. Transcriptome analysis of the lung and adipose tissue obtained from deceased COVID-19 patients found that the obese patients had an increase in the expression of genes and the activation of pathways associated with inflammation as compared to normal-weight patients (n = 2). The K18 mouse model and human COVID-19 patient data support a link between inflammation and an obesity-accelerated COVID-19 disease phenotype. These results also indicate that obesity-accelerated severe COVID-19 caused by SARS-CoV-2 WA1 infection in the K18 mouse model would be a suitable model for dissecting the cellular and molecular mechanisms underlying pathogenesis.
BACKGROUND: The optimal assessment of systemic and lung decongestion during acute heart failure is not clearly defined. We evaluated whether inferior vena cava (IVC) and pulmonary ultrasound (CAVAL US) guided therapy is superior to standard care in reducing subclinical congestion at discharge in patients with AHF.
METHODS: CAVAL US-AHF was an investigator-initiated, single-center, single-blind, randomized controlled trial. A daily quantitative ultrasound protocol using the 8-zone method was used and treatment was adjusted according to an algorithm. The primary endpoint was the presence of more than 5 B-lines and/or an increase in IVC diameter and collapsibility at discharge. And secondary endpoint exploratory outcome was the composite of readmission for HF, unplanned visit for worsening HF or death at 90 days RESULTS: Sixty patients were randomized to CAVAL US (n = 30) or control (n = 30). The primary endpoint was achieved in 4 patients (13.3%) in the CAVAL US group and 20 patients (66.6%) in the control group (P < .001). A significant reduction in HF readmission, unplanned visit for worsening HF or death at 90 days was seen in the CAVAL US group (13.3% vs 36.7%; log rank P = .038). Other endpoints such as NT-proBNP reduction at discharge showed a nonstatistically significant reduction in the CAVAL US group (48% IQR 27-67 vs 37% -3-59; P = .09). Safety outcomes were similar in both groups.
CONCLUSION: IVC and lung ultrasound-guided therapy in AHF patients significantly reduced subclinical congestion at discharge. CAVAL US-AHF provides preliminary evidence for the potential use of a simple technique to guide decongestive therapy during hospitalization for AHF, which may reduce the composite outcome at 90 days.
PROBLEM TO BE SOLVED: To obtain a surface-treated powder having excellent water resistance and ultraviolet light absorption as well as a lipophilic property to show a good dispersibility in an oily solvent, which is applicable to use in a dermatological compsn., a coating compsn., a resin compsn., and a container. SOLUTION: One or more of org. compds. having an atom and/or a polar group with a lone electron pair in the molecule and water, or a hydrolysis retarding agent in addn. thereto are added to a titanium alkoxide, an oily soln. thereof, or an oily dispersion thereof. The surface of a powder as a nucleus is surface-treated with one or more selected from the group consisting of a transparent oily dispersion of titanium dioxide obtd. by hydrolyzing the mixture, a film forming compsn. obtd. by condensing the dispersion or eliminating the dispersant from the dispersion, and a lipophilic titanium dioxide powder obtd. by eliminating the dispersant from the oily dispersion followed by drying or baking, in order to obtain a surface-treated powder. This powder is applied to a dermatological compsn., a coating compsn., and a resin compsn. as well as a container.
BACKGROUND: Locally advanced rectal cancer (LARC) is one of the most common malignant tumors worldwide, and its incidence is increasing year by year. Despite multimodal treatment, the recurrence rate of LARC patients remains high, about 20%-50%. However, the follow-up strategy according to tumor stage has certain limitations. There is no consensus on the optimal frequency and duration of follow-up. This study aims to comprehensively analyze the high-risk factors for recurrence in LARC from clinical characteristics, nutritional indicators, and imaging indexes. It intends to utilize conditional survival (CS) evaluation to assess dynamic survival and recurrence risks after comprehensive treatment of LARC and to develop individualized follow-up strategies.
METHODS: Logistic regression was utilized to analyze the independent recurrence factors in LARC patients. Calibration curve, decision curve, and ROC curve were employed to evaluate the model's efficacy. Kaplan-Meier curve was used to calculate CS rate and compare survival differences among different risk groups.
RESULTS: A total of 561 patients were analyzed in our study. Our multivariable logistic regression analysis revealed that the prognostic nutritional index (PNI), extramural vascular invasion (EMVI), vascular tumor thrombus, perineural invasion, and tumor size were independent factors for recurrence. Subsequently, a nomogram model was constructed and risk stratification was performed. Calibration curves and decision curves demonstrated that the model exhibited good clinical efficacy. The area under the ROC curve for the model was 0.763, indicating good sensitivity and specificity. Kaplan-Meier curves showed significant differences in survival among different risk groups. Furthermore, we observed that the CS without local recurrence and distant metastasis increased each year, while the cumulative recurrence risk decreased annually with prolonged survival time. Tailored follow-up intensities were developed for different risk groups and clinical stages based on the cumulative recurrence risk.
CONCLUSION: The personalized follow-up strategy based on risk stratification can optimize resource allocation, early detection of recurrence or metastasis, and ultimately enhance the overall care and prognosis of LARC patients.
The aim of this "Technical Note" is to inform the pediatric critical care data research community about the "2024 Pediatric Sepsis Data Challenge." This competition aims to facilitate the development of open-source algorithms to predict in-hospital mortality in Ugandan children with sepsis. The challenge is to first develop an algorithm using a synthetic training dataset, which will then be scored according to standard diagnostic testing criteria, and then be evaluated against a nonsynthetic test dataset. The datasets originate from admissions to six hospitals in Uganda (2017-2020) and include 3837 children, 6 to 60 months old, who were confirmed or suspected to have a diagnosis of sepsis. The synthetic dataset was created from a random subset of the original data. The test validation dataset closely resembles the synthetic dataset. The challenge should generate an optimal model for predicting in-hospital mortality. Following external validation, this model could be used to improve the outcomes for children with proven or suspected sepsis in low- and middle-income settings.
Epilepsy which affects over 70 million people worldwide, is one of the most common neurological diseases. Epilepsy is "a disease characterized by an enduring predisposition to generate epileptic seizures and by the neurobiological, cognitive, psychological, and social consequences of this condition." Therefore, self-management plays a crucial role for people with epilepsy (PWE) to adapt their lifestyles and behaviors for those long-lasting changes. Self-management is a dynamic, interactive, and daily process in which individuals engage to manage a chronic illness. Self-management is "the ability of the individual, in conjunction with family, community, and healthcare professionals, to manage symptoms, treatments, lifestyle changes, and psychosocial, cultural, and spiritual consequences of health conditions." Optimal self-management may improve self-efficacy, knowledge about epilepsy of PWE and family, medical compliance, and avoidance of seizure triggers.

Mobile health (mHealth) epilepsy application (apps) refers to any digital software (e.g., via the Internet, mobile device, wearable, or desktop platforms) capable of collecting, tracking, or sharing data while interacting with patients about their epilepsy health information. Recent studies have reported that mHealth applications improved the management of people with chronic illnesses, including epilepsy. In the digital era, smartphones are becoming more and more popular worldwide. In 2016, there were 24.8 million (30% of the population) smartphone users in Viet Nam, and this share is predicted to rise by 40 percent by 2021. Nanacara is an educational app for PWE to improve self-management.

A systematic review showed 20 English apps designed to improve self-management for PWE. Only one randomized clinical trial (RCT) study showed the effectiveness of mobile apps in increasing self-management for PWE. This result implied the lack of validation study related to the clinical use of the epilepsy apps. This study aims to determine the effectiveness of the epilepsy app for PWE to improve self-management.
On study night 1, participants will receive standard care (no headphones provided). On study night 2, these patients will wear Active Noise Cancelling headphones playing white noise.
Inherited von Willebrand disease (VWD) is considered the most common bleeding disorder. Its prevalence is approximately 1% in the general population but symptomatic patients are rarer (0.01%). It is caused by a partial or total quantitative deficiency (type 1 and type 3) or by a qualitative defect (type 2) of von Willebrand factor (VWF), a large multimeric protein that is required for platelet adhesion and serves as factor VIII (FVIII) carrier. Type 2 VWD is further divided in four subgroups (2A, 2B, 2M, and 2N) that are distinguished according to the nature of the VWF defect. Most patients with type 1 VWD can be treated with the synthetic vasopressin analogue desmopressin (DDAVP; 2-desamino-8-D-arginine vasopressin), whereas patients with type 3 VWD and most patients with type 2 VWD require concentrates containing VWF. Plasma-derived FVIII concentrates, which were initially developed for the treatment of haemophilia, contain large amounts of VWF and are used in patients for whom DDAVP treatment is deemed ineffective or contraindicated. Voncento® (CSL Behring) is a plasma-derived FVIII/VWF concentrate registered in France since 2015 for the treatment and prevention of bleeding events in patients with inherited VWD. OPALE is an observational study describing the use of human coagulation FVIII/VWF concentrate (Voncento®) to treat and prevent bleeding episodes in a French cohort of patients with inherited von Willebrand disease in the real life settings. The aim of the OPALE study is to describe the efficacy and the safety of Voncento® in the prophylaxis and treatment of haemorrhage or surgical bleeding.
PURPOSE:To prepare an immunopromoting agent having high safety, exhibiting excellent immunopromoting effect, and useful for the prevention and immunization of particular infectious diseases, by using the microbial cells and cell component of swine-originated Bordetella bronchiseptica, as active component. CONSTITUTION:The objective immunopromoting agent is composed of microbial cells or cell component of swine-originated Bordetella bronchiseptica (hereinafter abbreviated as B.b). The bacterial cells can be obtaind by culturing B.b in culture medium such as brain heart infusion agar medium containing 10% calf serum, and collecting and washing the proliferated cells. When the microbial cells are injected in combination with a formalin inactivated antigen of Babesia gibsoni (B.g) for the purpose of promoting the immunity to the B.g infectious diseases e.g. a hemocytozoonisis of dog having anemia as main symptom, B.b has the most strong promoting effect to the phagocitic actitivity of phagocyte compared with the case using other microbial strain (e.g. Corynebacterium anaerobium).
BACKGROUND: Atrial fibrillation (AF) is often associated with atrial fibrosis and oxidative stress. Neferine, a bisbenzylisoquinoline alkaloid, has been reported to exert an antiarrhythmic effect. However, its impact on Angiotensin II (Ang II) infusion-induced AF and the underlying mechanism remains unclear. This study aimed to investigate whether neferine alleviates Ang II-induced AF and explore the underlying mechanisms.
METHODS: Mice subjected to Ang II infusion to induce AF were concurrently treated with neferine or saline. AF incidence, myocardial cell size, fibrosis, and oxidative stress were then examined.
RESULTS: Neferine treatment inhibited Ang II-induced AF, atrial size augmentation, and atrial fibrosis. Additionally, we observed that Ang II increased reactive oxygen species (ROS) generation, induced mitochondrial membrane potential depolarization, and reduced glutathione (GSH) and superoxide dismutase (SOD) levels, which were reversed to some extent by neferine. Mechanistically, neferine activated the Nrf2/HO-1 signaling pathway and inhibited TGF-β/p-Smad2/3 in Ang II-infused atria. Zinc Protoporphyrin (ZnPP), an HO-1 inhibitor, reduced the anti-oxidative effect of neferine to some extent and subsequently abolished the beneficial effect of neferine on Ang II-induced AF.
CONCLUSIONS: These findings provide hitherto undocumented evidence that the protective role of neferine in Ang II-induced AF is dependent on HO-1.
In patients randomized to multiple brushing samples, subsequent brushings #2-7 will be labeled separately and consecutively and sent to cytology. The cytopathologist will review each specimen for cellularity using a previously validated scoring system and presence of malignancy (positive, highly suspicious, atypical, normal).
A non-colloidal solution comprises water, silver citrate and a counterion such as potassium or calcium. The silver citrate can be dibasic silver citrate. A non- colloidal solution comprises water and silver complexed with a complexing agent and optionally a counterion. The complexing agent can be an amino acid or a hydroxy acid. The solutions can be used to treat ulcers, burns, viral, fungal and bacterial infections. The solution can also be used in water and equipment sanitation and for retarding food contamination.
Participants who previously received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q16W. Participants who previously received placebo in a preceding study or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q16W. Participants who previously received blinded placebo Q8W will receive RO7234292 Q8W. Participants who previously received blinded RO7234292 Q16W will receive open-label RO7234292 Q16W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q16W. Participants who previously received open-label RO7234292 Q16W will receive open-label RO7234292 Q16W.
PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
FIELD: organic chemistry, chemical technology, medicine, pharmacy. SUBSTANCE: invention relates to derivatives of polyhydroxyalkyl-pyrazine of the formula (I)   used as active component in medicinal agent where R 1  means stereoisomeric forms of chain (II):  ; R 2  means hydrogen atom; R 3  means stereoisomeric forms of chain (III):  ; or R 2  means stereoisomeric forms of chain (II):   or (III):   and R 3  means hydrogen atom. Invention describes also methods of synthesis of compounds of the formula (I) based on thereof. Compounds show hypoglycaemic activity and can be used in therapy for prophylaxis and treatment of diabetes mellitus. EFFECT: improved method of synthesis, valuable medicinal properties. 12 cl
Systems, methods, and computer program products for recording and monitoring pain are disclosed. A device may record a date and time corresponding to a pain entry, a pain type corresponding to the pain entry, and a pain intensity corresponding to the pain entry. The device may further record a pain location on a body corresponding to the pain entry. The device may also display the pain entry. In various embodiments, the device may display a graphical pain representation superimposed over the pain location on the body. The device may also read an input encircling the pain location on the body. The device may further display a plurality of pain entries in a plot relative to time.
NEW MATERIAL:A benzylamine derivative of formula I [R1 is alkyl; R2 is group of formula II or III (R4 is H, lower alkyl or halogen); R3 is alkyl or alkenyl] and its acid addition salt. EXAMPLE:N-methyl-N-(4-tert-butylbenzyl)-1-naphthylmethylamine. USE:Useful as an antimycotic agent for pharmaceutical use, an agricultural fungicide and industrial fungicide. It can be safely used with little side effect. It has remarkable microbicidal activity against animal-parasitic fungi, phytopathogenic microorganism and various microorganisms causing deterioration of industrial materials and products, etc., and is effective in preventing various troubles caused by the above microorganisms. PREPARATION:The compound of formula I can be produced e.g. by reacting the compound of formula IV with the compound of formula V in an inert solvent in the presence of a basic substance preferably at room temperature - 60 deg.C.
The present invention relates to an injection and ointment for treating bromhidrosis. All kinds of bromhidrosis treating medicine at present belong to hardening agents, and large sweat glands can not be destroyed so as to be difficult for eradication. Liquid which is prepared from aluminum potassium sulfate, sodium citrate, tannic acid, carbolic acid and 50% anesthetic is adopted by the present invention as hypodermic injection. Sweat glands can be converged, and the secretion function of large sweat glands is inhibited, so that bromhidrosis is eradicated. Meanwhile, in order to strengthen the treatment effect, the ointment which comprises litharge, clove, pepper, chilli, red powder, calomel and camphor is also adopted and stuck to an affected position, so that the medicine partially penetrates into skin and further inhibits sweat glands to strengthen the treatment effect and prevent relapse. The cure rate of the present invention analyzed by more than 1000 clinical examples of medical history of more than three years reaches more than 95%.
The initial dose of Cyclosporine Capsules USP MODIFIED is 2.5 mg/kg/day, taken twice daily as a divided (BID) oral dose. Salicylates, NSAIDs, and oral corticosteroids may be continued (see WARNINGS and PRECAUTIONS, Drug Interactions). Onset of action generally occurs between 4 and 8 weeks. If insufficient clinical benefit is seen and tolerability is good (including serum creatinine less than 30% above baseline), the dose may be increased by 0.5 to 0.75 mg/kg/day after 8 weeks and again after 12 weeks to a maximum of 4 mg/kg/day. If no benefit is seen by 16 weeks of therapy, Cyclosporine Capsules USP MODIFIED therapy should be discontinued.

Dose decreases by 25% to 50% should be made at any time to control adverse events, e.g., hypertension elevations in serum creatinine (30% above patient’s pretreatment level) or clinically significant laboratory abnormalities (see WARNINGS and PRECAUTIONS).

If dose reduction is not effective in controlling abnormalities or if the adverse event or abnormality is severe, Cyclosporine Capsules USP MODIFIED should be discontinued. The same initial dose and dosage range should be used if Cyclosporine Capsules USP MODIFIED are combined with the recommended dose of methotrexate. Most patients can be treated with Cyclosporine Capsules USP MODIFIED doses of 3 mg/kg/day or below when combined with methotrexate doses of up to 15 mg/week (see CLINICAL PHARMACOLOGY, Clinical Trials).

There is limited long-term treatment data. Recurrence of rheumatoid arthritis disease activity is generally apparent within 4 weeks after stopping cyclosporine.
INTRODUCTION AND OBJECTIVES: Obstructive sleep apnea (OSA) is a prevalent condition among electable to bariatric surgery obese patients, often remaining underdiagnosed, thereby increasing surgical risk. The main purpose was to determine prevalence of OSA among candidates for bariatric surgery and to assess the rate of underdiagnosis of this condition. Additionally, the study aimed to evaluate the specific performance of three sleep questionnaires and scales (Excessive Daytime Sleepiness Scale (EDSS), Epworth Sleepiness Scale (ESS), and STOP-Bang) in these patients.
METHODS: A longitudinal, prospective, single-cohort study, with consecutive sampling including patients aged 18-65 years with obesity grade II (body mass index (BMI) ≥ 35 kg/m2) and hypertension, type 2 diabetes, metabolic syndrome or OSA or obesity grade III or IV (BMI ≥ 40 kg/m2) elective for bariatric surgery. Patients were evaluated at the Otorhinolaryngology department with an anamnesis regarding OSA including the administration of three sleep questionnaires (EDSS, ESS, and STOP-Bang), followed by cardiorespiratory polygraphy (CRP) for sleep evaluation.
RESULTS: 124 patients were included in this study. While 74.2% of the sample exhibited OSA on CRP, only 28.2% had a prior diagnosis. The STOP-Bang questionnaire demonstrated the highest sensitivity (93.3%) for detecting moderate to severe OSA, although with low specificity (33.8%). EDSS and ESS did not show a significant association with the presence of OSA.
CONCLUSIONS: OSA screening is crucial in candidates for bariatric surgery due to its high prevalence and low diagnosis rate. The STOP-Bang questionnaire may serve as a useful tool for identifying patients at risk of moderate to severe OSA and optimizing sleep assessments. However, further research is necessary to validate its utility in this specific population.
PURPOSE: To obtain a toothpaste capable of extremely controlling the fluidity of saliva and maintaining fluorine ion effects by blending a brushing cleaning agent such as silica or alumina abrasive not containing Ca and an inorganic ion fluoride with a spice and a sweetener while suppressing the spice and sweetener to small amounts. CONSTITUTION: This toothpaste comprises a brushing cleaning agent not containing calcium (e.g. a silica or alumina abrasive, a water-insoluble sodium metaphosphate or a plastic agent), an inorganic ion fluoride (e.g. sodium fluoride, sodium monofluorophosphate or its salt), 0.01-0.6wt.%, especially 0.01-0.5wt.% of a spice (e.g. peppermint oil or spearmint oil) and 0.002-0.1wt.%, especially 0.002-0.06wt.% of sodium saccharin salt or an equal amount of another sweetener. The toothpaste further may contain 0-1.5wt.%, especially 0-1.0wt.% of an anionic surfactant.
Patients receive 200mg pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.